EP Patent

EP1755590B1 — Combination of glycopyrrolate and a beta2 adrenoceptor agonist

Assigned to Novartis Pharma GmbH Austria · Expires 2011-08-24 · 15y expired

What this patent protects

A pharmaceutical composition containing (A) glycopyrrolate; and (B) a compound of formula Iin free or salt or solvate form, wherein W, R<sup>x</sup>, R<sup>y</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup&g…

USPTO Abstract

A pharmaceutical composition containing (A) glycopyrrolate; and (B) a compound of formula Iin free or salt or solvate form, wherein W, R<sup>x</sup>, R<sup>y</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>and R<sup>7</sup>have the meanings as indicated in the specification, together with at least one pharmaceutically acceptable carrier. The composition is useful in the treatment of inflammatory or obstructive airways diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP1755590B1
Jurisdiction
EP
Classification
—
Expires
2011-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Pharma GmbH Austria
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.